The VivoSight scanner has already won CE and Food and Drug Administration (FDA) regulatory clearance for clinical use in Europe and the US, and is now being trialled by skin cancer specialists.
The company says its VivoSight scanner will, for the first time, enable clinicians to see under the skin surface in real time, to help them decide whether to treat a lesion, what treatment to use and to show them how far a tumour has spread so that surgery is required only once.
This is expected to make non-melanoma skin cancer treatment more efficient and cost effective, as well as being better for the patient by reducing unnecessary surgery.
The investment from Octopus will help fund the manufacture and placement of VivoSight scanners for clinical and economic validation, as well as support the growth of the sales infrastructure in the UK and US.
Report highlights significant impact of manufacturing on UK economy
Note to Evil Villain/Dave 2020. Thatcher was PM for _11_ years, from 1979 to 1990 so no one under the age of 34 was even born when she left office....